Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,199 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Group A: Saline Group Clear all
Recruiting Phase 3 Interventional

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
56
States / cities
Sheffield, Alabama • Aurora, Colorado • Brooksville, Florida + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cervical Preparation for Same-Day Dilation & Evacuation

NCT06799052
View directory record Official record
Conditions
Abortion, Second Trimester, Procedural Pain, Procedural Complication
Interventions
Transcervical single-balloon catheter, Synthetic osmotic dilators
Device
Lead sponsor
Boston Medical Center
Other
Eligibility
16 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension

NCT03390426
View directory record Official record
Conditions
Tourniquet Hypertension, Intraoperative Hypertension, Total Ankle Arthroplasty, Ankle Fusion
Interventions
Mepivacaine, Perifemoral Injection of Local Anesthetic, Saline
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 1 Interventional

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

NCT03307915
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 4 Interventional Results available

Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine

NCT01709708
View directory record Official record
Conditions
Chronic Migraine
Interventions
Marcaine, Saline
Drug
Lead sponsor
Tian Medical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Ann Arbor, Michigan • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 19, 2026, 4:53 PM EDT
Terminated Phase 4 Interventional Results available

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

NCT01362205
View directory record Official record
Conditions
Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity, Alcohol Withdrawal Hallucinosis, Alcohol Withdrawal-Induced Delirium Tremens
Interventions
Dexmedetomidine, Placebos
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 89 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

NCT00442169
View directory record Official record
Conditions
West Nile Fever
Interventions
ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 19, 2026, 4:53 PM EDT
Recruiting Not applicable Interventional

CAMPR-II RWE TRIAL: A Saline-hydrated Allogeneic Dual-layer Amniotic Membrane Product or a Synthetic, Resorbable Polymeric Wound Matrix to a Coarsened Exact Matched Retrospective Control Cohort of Hard to Heal DFUs and VLUs

NCT07701590
View directory record Official record
Conditions
Wound, Foot, Diabetic Foot Ulcer (DFU), Venus Leg Ulcer
Interventions
Microlyte®, IP 1: Membrane Wrap - Hydro
Device
Lead sponsor
Capsicure, LLC
Network
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
7
States / cities
San Diego, California • Coral Gables, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Not applicable Interventional Results available

Orthostatic Hypotension Treatment on Rehab Unit

NCT01030874
View directory record Official record
Conditions
Orthostatic Hypotension, Falls
Interventions
Medication review, Nutrition/Salt intake, Education, Exercise, Drug Recommendations
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 19, 2026, 4:53 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Ghrelin and Beta Cell Function in Diabetes

NCT02440061
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Synthetic human AG, Arginine, 0.9% saline solution
Drug
Lead sponsor
Jenny Tong, MD, MPH
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

NCT03524118
View directory record Official record
Conditions
Respiratory Tract Infection, Respiratory Syncytial Virus
Interventions
Clesrovimab, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Weeks to 8 Months
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
17
States / cities
Aurora, Colorado • Homestead, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

NCT01272180
View directory record Official record
Conditions
Invasive Meningococcal Disease
Interventions
Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV., Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV., Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine., Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
10 Years to 25 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
8
States / cities
Birmingham, Alabama • Madera, California • Paramount, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of CJCV2 With and Without ALFQ

NCT05500417
View directory record Official record
Conditions
Campylobacter Infection
Interventions
ALFQ, CJCV2
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ZIKA Vaccine in Naive Subjects

NCT02952833
View directory record Official record
Conditions
Zika Virus Infection
Interventions
Saline, Zika Virus Purified Inactivated Vaccine (ZPIV)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women

NCT01965704
View directory record Official record
Conditions
Narcotic Addiction, Neonatal Abstinence Syndrome
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 45 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
San Francisco, California • San Jose, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 3 Interventional Results available

Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma

NCT01691508
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo, OCS (prednisone/prednisolone)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Long Beach, California • Denver, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 19, 2026, 4:53 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

NCT00298272
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate
Biological · Drug · Dietary Supplement
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
18
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 19, 2026, 4:53 PM EDT
Not yet recruiting Phase 4 Interventional

Pain with Differing Intraperitoneal Washes At the End of Laparoscopic Gynecologic Surgery

NCT06842771
View directory record Official record
Conditions
Laparoscopic Adnexal Surgery
Interventions
Normal Saline (0.9% NaCl), Marcaine hydrochloride without epinephrine 0.5%
Other · Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

NCT03052764
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence
Interventions
onabotulinumtoxinA, Placebo (saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 19, 2026, 4:53 PM EDT
Terminated Phase 4 Interventional Results available

Suprainguinal Fascia Iliaca (SIFI) Block Improves Analgesia Following Total Hip Arthroplasty

NCT02933671
View directory record Official record
Conditions
Hip Osteoarthritis, Primary Total Hip Arthroplasty, Pain
Interventions
Suprainguinal fascia iliaca (SIFI) block, Sham block, Ropivacaine, Saline
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients

NCT00410163
View directory record Official record
Conditions
Leukaemia, Lymphocytic, Chronic
Interventions
Ofatumumab 500mg, Ofatumumab 1000mg, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

NCT05046184
View directory record Official record
Conditions
Major Depressive Disorder, Healthy Controls
Interventions
Ketamine Hydrochloride, Midazolam injection
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

NCT01482221
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD6765 iv, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Chino, California • Lond Beach, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 19, 2026, 4:53 PM EDT
Recruiting Phase 4 Interventional

Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction

NCT06511232
View directory record Official record
Conditions
Anterior Cruciate Ligament Tear, Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture
Interventions
Intraosseous Morphine
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 40 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 19, 2026, 4:53 PM EDT